A Single Arm, Multicenter, Phase II Trial of RAD001 [everolimus] as Monotherapy in the Palliative Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma After Failure of Platinum-Based Chemotherapy.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary)
Indications Urogenital cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

09 Aug 2017 This trial has been Discontinued in Belgium, according to European Clinical Trials Database.
24 Mar 2012 Additional trial location added as reported by European Clinical Trials Database.
23 Jan 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight